← Leaderboards
Keith D Robertson
Mayo Clinic Rochester
$11,241,926
Attributed
$17,440,249
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,440,249 · 9
By mechanism
R01$16,709,833 · 7
R21$415,000 · 1
K22$315,416 · 1
Top collaborators
- Chen Liu14 shared
- Thai Huu Ho8 shared
Others in their field
Top investigators on “Genes”
- David Heimbrook · Leidos Biomedical Research, Inc.$413,811,031
- Richard A Gibbs · Baylor College Of Medicine$338,750,128
- Barton F Haynes · Duke University$304,076,400
- Stacey Gabriel · Massachusetts Institute Of Technology$241,252,013
- Eric S Lander · Whitehead Institute For Biomedical Res$211,825,987
- Richard K. Wilson · Washington University$195,881,965
Research focus
GenesEpigenetic ProcessMediatingDna MethylationMalignant NeoplasmsLinkPatternGrowthGenome-WideGenetic TranscriptionCell GrowthMethylationDna Modification MethylasesAffectIn VitroTumorGenome StabilityEventBaseCellsChromatinNeoplastic CellTumorigenesisDefect
Grant awards (45)
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma$539,540
R01 · FY2025 · CA · contact PI
RNA methylation as a novel effector of SETD2 in kidney cancer$188,636
R21 · FY2025 · CA · contact PI
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma$512,562
R01 · FY2024 · CA · contact PI
RNA methylation as a novel effector of SETD2 in kidney cancer$226,364
R21 · FY2024 · CA · contact PI
Synthetic Lethal Targeting of SETD2 in Renal Cell Carcinoma$554,891
R01 · FY2023 · CA · contact PI
Deciphering the interplay between H3K36 and DNA methylation in renal cancer$566,045
R01 · FY2022 · CA · contact PI
Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer$506,150
R01 · FY2022 · AA · contact PI
Deciphering the interplay between H3K36 and DNA methylation in renal cancer$577,597
R01 · FY2021 · CA · contact PI
Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer$506,150
R01 · FY2021 · AA · contact PI
Epigenetic Mechanisms Underlying Hepatitis C-Induced Hepatocarcinogenesis$596,382
R01 · FY2020 · DK · contact PI
Deciphering the interplay between H3K36 and DNA methylation in renal cancer$577,597
R01 · FY2020 · CA · contact PI
Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer$506,150
R01 · FY2020 · AA · contact PI
Epigenetic Mechanisms Underlying Hepatitis C-Induced Hepatocarcinogenesis$596,382
R01 · FY2019 · DK · contact PI
Deciphering the interplay between H3K36 and DNA methylation in renal cancer$560,270
R01 · FY2019 · CA · contact PI
Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer$506,150
R01 · FY2019 · AA · contact PI
Epigenetic Mechanisms Underlying Hepatitis C-Induced Hepatocarcinogenesis$601,776
R01 · FY2018 · DK · contact PI
Deciphering the interplay between H3K36 and DNA methylation in renal cancer$577,597
R01 · FY2018 · CA · contact PI
Epigenetic Heterogeneity as a Driver of Liver Disease and Cancer$520,900
R01 · FY2018 · AA · contact PI
Epigenetic Mechanisms Underlying Hepatitis C-Induced Hepatocarcinogenesis$620,487
R01 · FY2017 · DK · contact PI
De Novo Methyltransferase Function in Chromatin and Cancer$265,136
R01 · FY2017 · CA · contact PI
De Novo Methyltransferase Function in Chromatin and Cancer$265,136
R01 · FY2016 · CA · contact PI
Developmental pathways, environmental agents, and epigenetics in liver disease$576,972
R01 · FY2015 · AA · contact PI
De Novo Methyltransferase Function in Chromatin and Cancer$265,136
R01 · FY2015 · CA · contact PI
Developmental pathways, environmental agents, and epigenetics in liver disease$591,341
R01 · FY2014 · AA · contact PI
De Novo Methyltransferase Function in Chromatin and Cancer$257,181
R01 · FY2014 · CA · contact PI
Developmental pathways, environmental agents, and epigenetics in liver disease$560,612
R01 · FY2013 · AA · contact PI
De Novo Methyltransferase Function in Chromatin and Cancer$265,136
R01 · FY2013 · CA · contact PI
Developmental pathways, environmental agents, and epigenetics in liver disease$610,974
R01 · FY2012 · AA · contact PI
De Novo Methyltransferase Function in Chromatin and Cancer$245,126
R01 · FY2012 · CA · contact PI
Developmental pathways, environmental agents, and epigenetics in liver disease$630,122
R01 · FY2011 · AA · contact PI
De Novo Methyltransferase Function in Chromatin and Cancer$245,127
R01 · FY2011 · CA · contact PI
De Novo Methyltransferase Function in Chromatin and Cancer$255,185
R01 · FY2010 · CA · contact PI
DNA Methyltransferase Inhibition by Intercalating Agents$189,840
R01 · FY2010 · CA · contact PI
De Novo Methyltransferase Function in Chromatin and Cancer$255,185
R01 · FY2009 · CA · contact PI
DNA Methyltransferase Inhibition by Intercalating Agents$189,840
R01 · FY2009 · CA · contact PI
De novo methyltransferase function in chromatin & cancer$245,224
R01 · FY2008 · CA · contact PI
DNA Methyltransferase Inhibition by Intercalating Agents$134,321
R01 · FY2008 · CA · contact PI
DNA Methyltransferase Inhibition by Intercalating Agents$47,460
R01 · FY2008 · CA · contact PI
De novo methyltransferase function in chromatin & cancer$245,224
R01 · FY2007 · CA · contact PI
DNA Methyltransferase Inhibition by Intercalating Agents$187,241
R01 · FY2007 · CA · contact PI
De novo methyltransferase function in chromatin & cancer$252,548
R01 · FY2006 · CA · contact PI
DNA Methyltransferase Inhibition by Intercalating Agents$215,777
R01 · FY2006 · CA · contact PI
De novo methyltransferase function in chromatin &cancer$287,363
R01 · FY2005 · CA
MECHANISMS OF DE NOVO METHYLATION IN CANCER$157,708
K22 · FY2005 · CA
MECHANISMS OF DE NOVO METHYLATION IN CANCER$157,708
K22 · FY2004 · CA